Table 4. Cumulative number of acute and indeterminate Chagas cases identified and completing treatment and the impact of treating in Chagas disease in the acute and indeterminate stages on the number of chronic cases and median cost (95% uncertainty interval) over time when identifying and treating different percentages of patients annually.
| Percentage of Cases Identified and Completing Treatment Annually | Number Identified and Completing Treatment | Number New Chronic Cases | Third-Party Payer Costs | Societal Costs | DALYs |
|---|---|---|---|---|---|
| Year 1 | |||||
| No Treatment | - | 0.4 | 202 (125–294) | 2,025 (1,844–2,185) | 0.3 (0.2–0.3) |
| 5% | 1.6 | 0.4 | 310 (208–429) | 2,130 (1,945–2,308) | 0.3 (0.2–0.3) |
| 20% | 6.4 | 0.4 | 604 (393–998) | 2,424 (2,150–2,853) | 0.3 (0.2–0.3) |
| 50% | 16.0 | 0.4 | 1,195 (703–2,159) | 3,010 (2,486–4,018) | 0.3 (0.2–0.3) |
| 100% | 31.8 | 0.3 | 2,138 (1,223–4,168) | 3,986 (2,998–6,004) | 0.3 (0.2–0.3) |
| Year 5 | |||||
| No Treatment | - | 2.2 | 2,487 (1,541–3,628) | 24,959 (22,730–26,942) | 3.1 (2.5–3.6) |
| 5% | 5.1 | 2.1 | 2,772 (1,839–3,867) | 24,691 (22,580–26,597) | 3.0 (2.5–3.5) |
| 20% | 10.2 | 1.9 | 3,018 (1,998–4,148) | 23,873 (21,844–25,849) | 2.9 (2.3–3.3) |
| 50% | 20.2 | 1.6 | 3,390 (2,302–4,812) | 22,267 (20,118–24,250) | 2.6 (2.1–3.0) |
| 100% | 36.2 | 1.1 | 3,942 (2,568–6,273) | 19,284 (17,234–21,853) | 2.1 (1.7–2.5) |
| Year 10 | |||||
| No Treatment | - | 4.4 | 7,243 (4,488–10,565) | 72,679 (66,190–78,455) | 9.0 (7.3–10.4) |
| 5% | 9.4 | 4.0 | 7,481 (4,894–10,555) | 69,530 (63,548–74,882) | 8.6 (7.0–9.9) |
| 20% | 14.8 | 3.7 | 7,431 (4,933–10,414) | 65,249 (59,546–70,574) | 8.0 (6.5–9.3) |
| 50% | 24.9 | 3.0 | 7,178 (4,873–9,890) | 56,967 (51,731–61,478) | 6.8 (5.6–7.9) |
| 100% | 41.0 | 1.9 | 6,624 (4,266–9,504) | 42,872 (39,141–46,910) | 5.0 (4.1–5.8) |
| Year 20 | |||||
| No Treatment | - | 8.8 | 18,237 (11,301–26,602) | 182,994 (166,655–197,536) | 22.6 (18.3–26.2) |
| 5% | 17.9 | 7.5 | 17,463 (11,307–24,768) | 165,509 (151,252–178,296) | 20.5 (16.6–23.6) |
| 20% | 23.6 | 6.8 | 16,610 (10,781–23,565) | 152,698 (139,249–165,269) | 18.9 (15.3–21.8) |
| 50% | 34.1 | 5.5 | 14,751 (9,960–20,332) | 128,475 (116,747–138,396) | 15.6 (12.7–18.0) |
| 100% | 50.4 | 3.4 | 11,577 (7,582–15,962) | 88,451 (81,150–95,751) | 10.6 (8.7–12.3) |
| Year 30 | |||||
| No Treatment | - | 13.2 | 28,025 (17,366–40,880) | 281,211 (256,102–303,558) | 34.8 (28.1–40.2) |
| 5% | 26.2 | 10.5 | 25,395 (16,453–36,078) | 242,169 (221,342–260,936) | 30.1 (24.4–34.5) |
| 20% | 32.2 | 9.5 | 23,830 (15,385–34,007) | 221,931 (202,286–240,218) | 27.5 (22.2–31.7) |
| 50% | 43.1 | 7.7 | 20,607 (13,806–28,544) | 184,083 (167,355–198,326) | 22.5 (18.3–25.9) |
| 100% | 59.5 | 4.8 | 15,317 (9,981–21,042) | 123,212 (113,218–133,257) | 14.9 (12.2–17.3) |
| Year 40 | |||||
| No Treatment | - | 17.6 | 35,770 (22,165–52,176) | 358,922 (326,874–387,444) | 44.4 (35.9–51.3) |
| 5% | 34.3 | 13.2 | 31,015 (20,104–44,093) | 296,507 (270,985–319,480) | 36.8 (29.9–42.3) |
| 20% | 40.7 | 11.9 | 28,915 (18,629–41,316) | 270,549 (246,520–292,862) | 33.5 (27.1–38.6) |
| 50% | 52.0 | 9.5 | 24,745 (16,550–34,277) | 222,746 (202,580–239,989) | 27.2 (22.2–31.4) |
| 100% | 68.6 | 6.0 | 17,960 (11,634–24,531) | 147,414 (135,525–159,329) | 17.9 (14.6–20.7) |
| Year 50 | |||||
| No Treatment | - | 22.0 | 41,665 (25,818–60,775) | 418,074 (380,745–451,297) | 51.7 (41.8–59.7) |
| 5% | 42.3 | 15.7 | 34,874 (22,607–49,576) | 333,688 (304,954–359,541) | 41.4 (33.6–47.6) |
| 20% | 49.1 | 14.1 | 32,386 (20,838–46,295) | 303,506 (276,540–328,573) | 37.6 (30.4–43.4) |
| 50% | 60.7 | 11.2 | 27,515 (18,381–38,148) | 248,808 (226,286–268,023) | 30.4 (24.8–35.0) |
| 100% | 77.5 | 7.0 | 19,756 (12,730–26,997) | 163,830 (150,721–177,182) | 19.9 (16.3–23.1) |
DALYs = disability-adjusted life years